Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.
Chou
Sunwen
S
Division of Infectious Diseases, Oregon Health & Science University, Portland, OR, USA. chous@ohsu.edu
Marousek
Gail
G
Boivin
Guy
G
Goyette
Nathalie
N
Farhan
Mahdi
M
Ives
Jane A L
JA
Elston
Robert
R
D000998:Antiviral Agents / Q000627:therapeutic use*; D001483:Base Sequence; D003587:Cytomegalovirus / Q000187:drug effects / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000235:genetics*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D013997:Time Factors; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir